NxStage Medical Inc. (NASDAQ:NXTM) President Joseph E. Turk, Jr. sold 12,169 shares of the stock in a transaction that occurred on Monday, November 28th. The shares were sold at an average price of $26.01, for a total value of $316,515.69. Following the transaction, the president now directly owns 86,780 shares of the company’s stock, valued at $2,257,147.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of NxStage Medical Inc. (NASDAQ:NXTM) opened at 24.72 on Thursday. NxStage Medical Inc. has a one year low of $13.49 and a one year high of $26.83. The stock’s market capitalization is $1.60 billion. The stock has a 50 day moving average price of $24.31 and a 200 day moving average price of $22.70.

Insider Buying and Selling by Quarter for NxStage Medical (NASDAQ:NXTM)

ILLEGAL ACTIVITY NOTICE: “Joseph E. Turk, Jr. Sells 12,169 Shares of NxStage Medical Inc. (NXTM) Stock” was originally published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2016/12/01/joseph-e-turk-jr-sells-12169-shares-of-nxstage-medical-inc-nxtm-stock.html.

Several institutional investors have recently made changes to their positions in NXTM. Price T Rowe Associates Inc. MD acquired a new position in shares of NxStage Medical during the third quarter valued at $207,000. Chartwell Investment Partners LLC boosted its stake in NxStage Medical by 28.7% in the third quarter. Chartwell Investment Partners LLC now owns 406,005 shares of the medical device company’s stock valued at $10,146,000 after buying an additional 90,485 shares during the last quarter. Mackenzie Financial Corp boosted its stake in NxStage Medical by 42.1% in the third quarter. Mackenzie Financial Corp now owns 55,370 shares of the medical device company’s stock valued at $1,384,000 after buying an additional 16,401 shares during the last quarter. Panagora Asset Management Inc. boosted its stake in NxStage Medical by 573.3% in the third quarter. Panagora Asset Management Inc. now owns 76,560 shares of the medical device company’s stock valued at $1,913,000 after buying an additional 65,189 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. boosted its stake in NxStage Medical by 29.5% in the third quarter. D. E. Shaw & Co. Inc. now owns 316,312 shares of the medical device company’s stock valued at $7,905,000 after buying an additional 71,964 shares during the last quarter.

A number of equities research analysts have issued reports on NXTM shares. Zacks Investment Research upgraded NxStage Medical from a “hold” rating to a “buy” rating and set a $27.00 price objective on the stock in a research report on Tuesday, August 9th. Canaccord Genuity restated a “buy” rating and set a $28.00 price objective on shares of NxStage Medical in a research report on Thursday, November 3rd. BTIG Research restated a “buy” rating and set a $29.00 price objective on shares of NxStage Medical in a research report on Sunday, August 7th. Jefferies Group upped their price objective on NxStage Medical from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Friday, August 5th. Finally, Northland Securities set a $25.00 price objective on NxStage Medical and gave the company a “buy” rating in a research report on Thursday, September 15th. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $25.67.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company is engaged in the development, manufacturing and marketing of products and services for patients suffering from chronic or acute kidney failure. The Company operates through three segments: System One, In-Center and Services. It offers its products and services to various markets, such as home, critical care and in-center.

5 Day Chart for NASDAQ:NXTM

Receive News & Stock Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related stocks with our FREE daily email newsletter.